Entrada Therapeutics Financial Results
Entrada Therapeutics reported third quarter 2026 financial results and provided updates on its clinical pipeline, including its ELEVATE-44-201 and ELEVATE-45-201 programs for Duchenne muscular dystrophy. The company ended the quarter with $193 million in cash, extending its expected runway into Q4 2027. Multiple clinical data readouts are expected through the first half of 2027, including data from its DM1 partnership with Vertex.
“The October Cohort 1 data from ELEVATE-45-201 marked our third consecutive readout demonstrating encouraging safety and tolerability across our clinical programs. With these initial dose cohorts supporting the safety profile of our lead Duchenne programs, our attention now turns to the next set of readouts designed to further define the potential of our investigational medicines.”
Dipal Doshi, Chief Executive Officer of Entrada Therapeutics
“Including the anticipated Phase 1/2 clinical data from our partner Vertex’s GALILEO study in myotonic dystrophy type 1 during the second half of 2026, we expect four clinical data readouts through the first half of 2027. This marks an important period of clinical catalysts for Entrada as we advance our pipeline and work toward our goal of delivering potentially transformative medicines to people living with serious neuromuscular diseases.”
Dipal Doshi, Chief Executive Officer of Entrada Therapeutics